TY  - JOUR
AU  - Argüelles-Arias, F
AU  - Guerra Veloz, M F
AU  - Perea Amarillo, R
AU  - Vilches-Arenas, A
AU  - Castro Laria, L
AU  - Maldonado Pérez, B
AU  - Chaaro, D
AU  - Benítez Roldán, A
AU  - Merino, V
AU  - Ramírez, G
AU  - Caunedo Álvarez, A
AU  - Romero Gómez, M
PY  - 2017
DO  - 10.1007/s10620-017-4511-4
UR  - http://hdl.handle.net/10668/10954
T2  - Digestive diseases and sciences
AB  - CT-P13 is a biosimilar of Remicade®, an agent approved in some countries for use in inflammatory bowel disease (IBD). Controlled clinical trials have demonstrated the efficacy and safety of CT-P13 in rheumatic diseases, but not in IBD. To assess the...
LA  - en
KW  - Biosimilar agent
KW  - CT-P13
KW  - Crohn’s disease
KW  - Infliximab
KW  - Ulcerative colitis
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Drug Administration Schedule
KW  - Female
KW  - Humans
KW  - Inflammatory Bowel Diseases
KW  - Male
KW  - Middle Aged
KW  - Prospective Studies
KW  - Remission Induction
TI  - Effectiveness and Safety of CT-P13 (Biosimilar Infliximab) in Patients with Inflammatory Bowel Disease in Real Life at 6 Months.
TY  - research article
VL  - 62
ER  -